Clarity Medical Group Holding Limited has released the principal findings of an independent forensic investigation by Grant Thornton Advisory Services (GT) into allegations that its 2022 IPO prospectus overstated profits and concealed dividend-re-routing and remuneration arrangements.
GT’s work—covering the period from 1 April 2018 to 31 August 2022—focused on four areas: remuneration structures for senior doctors, alleged undisclosed loans, a HK$148.00 million dividend re-direction and set-off, and the post-listing termination of consultancy agreements. The forensic team reviewed accounting data, bank statements and computer forensics, and conducted interviews, but faced gaps in historical records and limited access to certain former executives and entities.
Key conclusions are as follows:
1. Remuneration shift substantiated; no proof of undisclosed loans • The move in FY2016/17 to fixed monthly fees of HK$100,000–HK$200,000 for Dr. Teresa Lau and Dr. Yung Lam Hui was corroborated by the Group’s books and prospectus disclosures. • GT did not substantiate allegations that the Group had loaned funds to Dr. Wai Yip Tse for onward payment to the two doctors. While fund transfers from the Group to entities controlled by Dr. Tse and subsequent payments to the doctors’ service companies were identified, no documentary evidence confirmed a Group-level obligation to compensate remuneration shortfalls.
2. Dividend Distribution & Set-off verified, commercial rationale unclear Executed resolutions show that pre-IPO dividends of HK$148.00 million were directed to Dr. Tse’s vehicle, Ultimate Bliss Ltd, and offset against balances owed by Dr. Tse and CMGL to the Group. GT confirmed the mechanics but, owing to missing records and unavailable personnel, could not determine the underlying decision-making process.
3. Consultancy terminations confirmed without clear motive The fixed-fee agreements with Dr. Hui and Dr. Lau ended in early 2022; both later entered new contracts on different terms. GT verified the cessation of payments and services but could not establish whether regulatory considerations prompted the terminations.
4. Limited impact on listing profit requirement GT’s illustrative recalculation—assuming the doctors had continued to earn variable pay—indicates adjusted net profit for the three years to 31 March 2021 and the four months to 31 July 2021 would have been HK$78.97 million, versus HK$87.45 million disclosed in the prospectus. Even under this scenario, the company would still have surpassed the HKEX Rule 8.05(1)(a) minimum profit threshold.
5. Prospectus largely consistent; some disclosures unresolved While most prospectus data aligned with GT’s findings, omissions were noted on additional payments by the doctors’ entities, the dividend re-direction, and receivable assignments. Due to evidence gaps, GT could not conclusively rule on material misstatement or omission.
6. Internal control deficiencies rectified Weaknesses—primarily insufficient approvals for advances and incomplete payroll support—have been addressed. An independent adviser has confirmed full implementation of recommended remedial measures.
All individuals linked to the queried transactions have left the Group, and GT found no indication that current directors or senior management engaged in misconduct. Trading in Clarity Medical’s shares (HKEX: 01406) has been suspended since 15 April 2025 and remains halted pending further notice.
Comments